Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
F-box only protein 7 (FBXO7)
- Target
- FBXO7
- Molecular classification
- F-box protein, Component of SCF (Skp1-Cullin-F-box) E3 ubiquitin ligase complex, Enzyme (E3 ubiquitin ligase), Other (Proteasome regulator)
01
Overview
F-box only protein 7 (FBXO7) is a member of the F-box protein family that serves as the substrate recognition component of the SCF (Skp1-Cullin-F-box) E3 ubiquitin ligase complex. FBXO7 directs the ubiquitination and consequent degradation of selected target proteins, and also has noncanonical roles including regulation of proteasome activity, modulation of cell cycle transition (mainly through actions on Cdk6 and p27), cellular differentiation, and the regulation of mitophagy in cooperation with the PINK1 and Parkin pathway. Mutations in FBXO7 cause autosomal recessive early-onset parkinsonism (PARK15)[1][2][3][4][5].
- Other names
- F-box protein 7FBX7FbxPARK15PKPSFBXFBX07
02
Mechanism of action
Drugs theoretically targeting FBXO7 would be expected to inhibit or modulate its ubiquitin ligase activity, alter substrate recruitment, or modulate its role in mitophagy, proteasomal regulation, or cell cycle control[1][4][3].
03
Biological functions
Ubiquitination of substrate proteinsRegulation of the cell cycleRegulation of proteasome activityMitophagy (mitochondrial quality control)Cell differentiation
04
Disease associations
Neurodegenerative disease (notably early-onset parkinsonism/Parkinson disease 15)Other (potential roles in hematopoiesis and cell proliferation)
05
Safety considerations
As FBXO7 plays roles in fundamental processes such as cell cycle regulation and mitochondrial quality control, targeting this molecule could risk unintended effects on cell proliferation, differentiation, mitophagy, and neurodegeneration, thus posing a risk of cytotoxicity or worsening of neurodegenerative symptoms[1][5][4].
06
Biomarkers
Mutations in FBXO7 serve as biomarkers for autosomal recessive early-onset parkinsonism (PARK15)[2][5].
Beyond the preview
Go deeper on F-box only protein 7 (FBXO7).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on F-box only protein 7 (FBXO7).